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In recent decades, tumor surveillance by the immune system and its impact on disease
outcomes in cancer patients in general and in breast cancer (BC) patients in particular
has been documented. Natural killer (NK) cells are central components of the innate
immunity and existing data indicate that they play a role in preventing and controlling tumor
growth and metastasis. Their biological significance was first recognized by their ability to
exert direct cellular cytotoxicity without prior sensitization. This is important in tumors, as
transforming events are likely to result in downregulation of self-ligands and expression of
stress-induced ligands which can be recognized by NK cells. Their activation also leads to
secretion of stimulatory cytokines which participate in cancer elimination by several direct
mechanisms as well as by stimulating the adaptive immune system. In this regard, it
was recently revealed a dendritic cell (DC)-NK-cell crosstalk which provides another novel
pathway linking innate and adaptive immunity. In addition, NK cells are feasible targets
of stimulation in immunotherapeutic approaches such as antibody-based strategies and
adoptive cell transfer. Nevertheless, NK cells display impaired functionality and capability
to infiltrate tumors in BC patients. This review compiles information about NK-cell biology
in BC and the attempts which aim to manipulate them in novel therapeutic approaches in
this pathology.
Keywords: natural killer (NK) cells, breast cancer, immunotherapy, immunosuppression, monoclonal antibodies
INTRODUCTION
Natural killer (NK) cells have been first described as innate
effector lymphocytes and their biological significance has been
first recognized by their ability to exert direct cellular cyto-
toxicity without prior sensitization (Herberman et al., 1975;
Kiessling et al., 1975). The missing-self hypothesis established
by Klas Kärre and collaborators postulates that NK cells rec-
ognize and eliminate their target cells by sensing the loss of
self-major histocompatibility complex (MHC) class I molecules
(Karre et al., 1986; Ljunggren and Karre, 1990). As counter-
part, when MHC class I inhibition is absent, the NK-cell must
still be stimulated through activation receptors. For instance, the
upregulation of stress signals switched on in cells under stress
triggers NK-cell activation (Bauer et al., 1999). Alternatively,
FcγIII receptor CD16 binds the Fc portion of antibodies and
trigger an antibody-dependent cellular cytotoxicity (ADCC) on
opsonized target cells (Titus et al., 1987). The regulation of
effector function of NK cells then depends on the integra-
tion of these positive and negative signals sensed on target
cells. This is particularly important in tumors, as the events
leading to transformation are likely to result in downregula-
tion of self-ligands and expression of stress-induced ligands
by tumor cells which can then be recognized by NK cells
(Bottino et al., 2005; Garrido et al., 2010).
IN VIVO EVIDENCE OF BC CONTROL BY NK CELLS IN A
MOUSE MODEL
Mouse models of human malignancies have contributed
significantly to the understanding of disease pathogenesis as well
as for preclinical therapeutic studies. Although several models
mainly using conventional SCID mice are available, the major
drawback is they still retain NK-cell, macrophage, complement,
and dendritic cell (DC) activities. In contrast, NOD/SCID/γnull
(NSG) mice lack T, B, and NK cells which makes them a suit-
able model for tumor engraftment and to investigate the role
of NK in tumor growth and metastasis (Ito et al., 2002). Using
these models, the direct role of NK cells in tumor growth and
metastasis was demonstrated in vivo by comparing NSG to con-
ventional SCID mice. NSG mice inoculated with breast cancer
(BC) cells were most efficient in the formation of large tumors
within 2–3 weeks in all mice. Moreover, activated NK cells inhib-
ited tumor formation and organ metastasis, suggesting that NK
cells are responsible for inhibiting the formation of progressively
growing rapid large tumors of BC cells in SCID mice (Dewan
et al., 2007). A similar approach comparing wild type to NSG
with BC cells showed that suppression of an Irf7-driven cluster of
IFN-regulated genes is crucial to the establishment of bonemetas-
tases. Data showed that functional NK cells and CD8+ lympho-
cytes were both necessary for Irf7-induced and IFN-dependent
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immune activation to confer protection against metastasis but
suggested that tumor immunosurveillance does not regulate the
initiation of primary breast tumors. Furthermore, the clinical
relevance of these findings was underscored in analyses of human
primary tumors which revealed that high expression of the Irf7-
regulated genes in patients with BC was associated with less
relapses to bone (Bidwell et al., 2012).
BC BIOLOGY AND NK CELLS
Human breast tumors can be categorized as luminal subtype
A, luminal subtype B, HER-2+, basal subtype, normal breast-
like, and the recently introduced Claudin-low subtype, based
on their molecular characteristics (Sorlie, 2004; Prat et al.,
2010). However, differential gene expression patterns in breast
tumor stroma led to the identification of subtypes correspond-
ing to good and poor-outcome BCs independently of molecular
tumor type. Interestingly, tumor stroma samples from the good-
outcome cluster overexpress a distinct set of immune-related
genes, including T-cell and NK-cell markers indicative of a TH1-
type immune response (granzyme A, CD52, CD247, and CD8A)
(Finak et al., 2008). Although there is no evidence to date for
an association between NK-cell infiltrate and clinical outcome
in patients with BC, the expression of NK-cell ligands does
play a crucial role in tumor immunoediting and concomitant
immune escape in BC. This evidence arose from studies of prog-
nostic value of non-classical HLA class I molecule expression
in BC patients which showed that in tumors devoid of classi-
cal HLA class I expression, HLA-E and HLA-G expression were
of statistically significant influence on outcome of BC patients
independently of known clinicopathological parameters, with an
almost three-times higher risk of relapse over time for patients
with expression of HLA-E/G compared with patients with no
expression of HLA-E/G (De Kruijf et al., 2010). Furthermore, an
analysis of the clinical prognostic value of the activating NK-cell
receptor NKG2D ligands MIC-AB and ULBP1-5 in early stage
BC revealed that expression of MIC-AB and ULBP-2 results in
a favorable outcome concerning relapse-free survival (De Kruijf
et al., 2012). Microarray data for NK-cell ligand expression in pri-
mary breast tumors showed that the different subtypes express
heterogeneous levels of inhibitory HLA members, while some
patterns of ligand expression represented the different molecular
subtypes, which are characterized by distinct genomic alterations
and deriving from different precursor cells, except for NKG2D
and DNAM-1 ligands which are expressed in virtually all breast
tumors regardless molecular subtype (Mamessier et al., 2011a).
Besides the described alterations in tumor molecules, there are
several studies that have shown that peripheral blood NK cells
from BC patients have impaired functionality as well (Garner
et al., 1983; Dewan et al., 2009; Mamessier et al., 2011b), con-
tributing to tumor escape from NK-cell control. Indeed, tumor
infiltrating NK cells display a striking phenotype with downreg-
ulation of activating receptors and the upregulation of inhibitory
receptors, and evidence suggests that the tumor induces its own
tolerance from NK-cell antitumor immunity (Mamessier et al.,
2011a,b). Altogether, the analysis of these data revealed that, on
the one hand, genomic variability and associated tumorigenic fea-
tures observed in BC resulted of some successful immunoedition
and, on the other hand, the existence of mechanisms possibly
used by breast tumor cells to immunosubvert NK cells. From this,
current efforts are focusing in identifying potential targets which
would contribute to enhance anti-tumor efficiency (Mamessier
et al., 2012).
Aside from direct tumor immune evasion, NK cells are the
target of multiple indirect tumor escape mechanisms such as gen-
eration and maintenance of T regulatory cells (Ghiringhelli et al.,
2006), and myeloid derived suppressor cells (Condamine and
Gabrilovich, 2011). The pathological relevance of this tolerogenic
and immunosuppressant environment has lately been brought
up in tumor models and in patients with BC (Wolf et al.,
2003; Sceneay et al., 2012). Consequently, further assessment
of the presence of these mechanisms in BC patients should
be considered for a better understanding of the complexity
of immunoevasion and for designing successful NK-cell-based
immunotherapy of BC.
NK CELLS IN BC THERAPEUTICS
NK-CELL-BASED IMMUNOTHERAPIES
Manipulating the immune system for therapeutic benefit in can-
cer patients has been studied for well over 100 years. Targeted
treatments and immunotherapy are two of the most promis-
ing approaches to cancer, and each could be improved by basic
research on NK cells. NK cells-based immunotherapy in BC
patients has two main approaches. One of them proposes the
direct administration of these cells stimulated ex vivo, whereas the
second one involve the administration of drugs, mainly cytokines,
to stimulate NK cells in the patients themselves. Although, there
have been great efforts to stimulate NK cells in adoptive therapies,
remaining challenges are related to the maintenance of NK-cell
stimulation over time and to obtain improved clinical outcomes.
The first clinical trials were developed in the early nineties and
continue to the present. The most important clinical trials using
NK-cell-based immunotherapy are listed in Table 1.
THERAPEUTIC ANTIBODIES AND NK CELLS
Targeting therapies with monoclonal antibodies (mAbs) are
also important therapeutic strategies for cancer. The mAb
trastuzumab has been approved for clinical use and has become
a mainstay for HER2-positive BC (Slamon et al., 2001). Clinical
efficacy is believed to rely mainly on the interference with the
HER2 oncogenic signaling. In addition, one of the potential
mechanisms of action of trastuzumab is NK-cell-mediated ADCC
of the HER2-positve target cells. In this sense, the HER2 sub-
type is perhaps today the BC subtype in which we can explore
the direct activity of NK cells in therapeutics. Trastuzumab-
mediated ADCC potency displayed by peripheral blood NK cells
was shown to be correlated with the short-term response to treat-
ment in metastatic BC patients (Beano et al., 2008). Further
examination of factors affecting ADCC intensity and variabil-
ity showed that the ability to develop ADCC in patients was
significantly dependent on the quantity of CD16+CD56+ lym-
phocytes among Peripheral blood Mononuclear Cell (PBMC).
However, when quantity was normalized to target cell num-
ber, there was a relationship between CD16-158V/F polymor-
phism and the killing efficiency of CD16+CD56+ cells (Varchetta
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et al., 2007). However, the largest retrospective analysis to date
evaluating an association between FCGR3A/2A genotypes and
clinical outcome in trastuzumab-treated HER2-positive BC in
the adjuvant setting showed no statistically significant correla-
tion between FCGR3A and FCGR2A genotypes and disease-free
survival in a cohort of 1286 patients treated with trastuzumab-
based therapy in early BC nor in progression-free survival in 53
women treated with trastuzumab-based therapy for metastatic
BC (Hurvitz et al., 2012). While these data do not entirely dis-
miss the possibility that trastuzumab triggers ADCC as one
of its mechanisms of action, it does suggest that any differ-
ences in Fc-FcγR affinity attributed to the polymorphisms tested
does not result in detectable differences in clinical outcome. In
fact, other evidence supporting the ADCC role in trastuzumab
therapeutic action was also demonstrated. E-cadherin-expressing
HER2-overexpressing BC cells were induced to treatment resis-
tance toward trastuzumab, because ADCC activity was inhibited
by interaction with E-cadherin and KLRG1 (Yamauchi et al.,
2011). Recently, a novel N-terminal fragment of HER2 was char-
acterized (H2NTF) and found to be frequently expressed in
breast tumor samples at variable levels. H2NTF is devoid of
the tyrosine kinase domain but it readily interacts with full-
length HER2 and other HER receptors. Therefore, H2NTF acts
as a dominant negative, attenuating the signaling triggered by
full-length HER receptors. Expression of H2NTF results in resis-
tance to the treatment with low concentrations of trastuzumab
in vitro. However, cells expressing H2NTF and non-expressing
cells have similar sensitivity to trastuzumab in vivo, indicating
that H2NTF/trastuzumab complexes trigger ADCC (Morancho
et al., 2012). Given the significance of the ADCC as antitu-
mor function, it is reasonable to think that the efficiency of the
host immune system could influence the responses to current
therapy regimens. Recently, an immunophenotypic profiling of
circulating and intratumor immune cells determined that com-
pared to HER2-cases, patients with HER2-overexpressing locally
advanced BC show a more limited tumor-related immune sup-
pression (Muraro et al., 2011). This may account for the clin-
ical benefit achieved in this subset of patients with the use of
drugs acting through, but also promoting, immune-mediated
effects.
Based on its ADCC mechanism, the anti-tumor efficacy
of trastuzumab can be enhanced by means of combination
with other immunomodulatory approaches such as chemother-
apy, radiotherapy, targeted therapy agents, vaccines, or other
immunomodulators. Table 1 also shows clinical trials that
demonstrate the use and effectiveness of trastuzumab combined
with different agents.
Experience with trastuzumab arouses the hope that mAbs
could be used in other BC subtypes. Particularly important is
the need for target therapies in basal BC as these patients are
not likely to benefit from anti-estrogen or anti-HER2 therapy,
and first-line treatment usually consists of conventional cyto-
toxic chemotherapy. Although basal BCs are quite sensitive to
chemotherapeutic regimens in the preoperative setting, they are
nevertheless associated with poor long-term outcomes (Liedtke
et al., 2008). Nevertheless, better prognosis groups of basal BCs
were identified on the basis of the expression of genes involved
Frontiers in Immunology | NK Cell Biology December 2012 | Volume 3 | Article 375 | 8
Roberti et al. Natural killer cells and breast cancer
in antitumor immunity (Teschendorff et al., 2007; Sabatier et al.,
2011a,b). As epidermal growth factor receptor (EGFR) is a tar-
getable receptor frequently overexpressed in basal BC, currently
cetuximab, a mAb that binds EGFR, is being tested for efficacy in
TNBC (Carey et al., 2012) and it was also shown in vitro that it
triggers NK-cell-mediated ADCC (Roberti et al., 2011).
NK-CELL—DC CROSSTALK
Besides effector functions for tumor elimination and cytokine
production, NK cells have mechanisms for stimulating the adap-
tive immune system, thus, being instrumental for enhancing
antigen processing and presentation. Recent studies illustrate the
potential of NK cells to increase the immunostimulatory capac-
ity of DCs. It was demonstrated that NK cells can efficiently
promote maturation and differentiation of DCs toward a Th1
profile (Mailliard et al., 2003). Hence, by inducing DC activation,
NK-cell activation induced by tumor cells can indirectly pro-
mote antitumoral T-cell responses. Reciprocally, activated DCs
induce potent NK-cell activation. Thus, NK-cell/DC crosstalk
coordinates innate and adaptive immune responses influencing
the quality and strength of the global immune response (Moretta
et al., 2006). In line with this, it was recently identified that the
interaction of cetuximab with EGFR on BC tumor cells and FcγR
IIIa on NK cells enhances cross-presentation of tumor antigens,
such as EGFR, by DC to cytotoxic T lymphocytes (Lee et al.,
2011). Regarding the evidence in clinical studies, correlation of
clinical responses in DC vaccine treated patients was reported. A
phase I/II trial of an autologous DC vaccine combined with IL-2
induced specific immunity against introduced antigens and mod-
ifications of immunological parameters such as antigen-specific
immune induction and NK-cell activation along with reduction
of inhibitory immunity in vaccinated patients (Baek et al., 2011).
However, the effect on the NK-cell population might be due to
the IL-2 administration. In a more recent study of only autol-
ogous DC-based immunotherapy in treatment of stage II/IIIA
BC patients data supports a correlation between positive immune
responses induced by DC vaccination and improved long-term
progress-free patient survival. DC vaccination was capable of pro-
moting secretion of Th1 cytokines, as well as of significantly
increased the number of peripheral blood NK cells and leding to
tumor-specific CD8+ T-cell expansion and further differentiation
into IFN-γ-producing effector cells (Qi et al., 2012).
PERSPECTIVES
The compiling evidence of NK-cell biology in BC sheds light on
the mechanisms involved in NK-cell tumor evasion and high-
lights the role of NK cells in the control of invasive breast tumors.
However, regarding tumor strategies to overcome its elimination
by innate immunity, it stresses the necessity of attempts which
aim not only to stimulate NK cells directly but to target the tumor
counterattack mechanisms in order to obtain clinical success in
novel therapeutic approaches to battle this complex pathology.
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